[Allergen specific immunotherapy for rhinitis allergica : New applications]

Area of Science:

• Immunology and Allergy Research
• T-lymphocyte mediated immune responses
• Th2-cytokine profiles in allergic diseases

Context:

• Allergic diseases are highly prevalent globally.
• Current treatments for allergies are often palliative.
• Allergen-specific immunotherapy (AIT) is the sole causative treatment.

Purpose:

• To review the efficacy and safety of novel immunotherapy routes.
• To explore intralymphatic immunotherapy (ILIT) and epicutaneous immunotherapy (EPIT).
• To identify areas for future clinical research in AIT.

Summary:

• Intralymphatic immunotherapy (ILIT) demonstrates high potency with minimal side effects, comparable to standard AIT.
• Epicutaneous immunotherapy (EPIT) is a safe and effective minimally invasive method, showing dose-dependent efficacy.
• Further research is needed to optimize ILIT and EPIT, including dosage, allergen formulations, and applicability to various allergic conditions and pediatric populations.

Impact:

• Novel AIT delivery methods like ILIT and EPIT may offer improved patient outcomes.
• These advancements could lead to more accessible and effective allergy treatments.
• Future clinical studies are crucial for validating and refining these new therapeutic approaches.